Active Biotech: New data from the Phase 2 LEGATO-HD study will be presented at HSG 2018
November 08 2018 - 7:00AM
PRESS RELEASE
New data from the Phase 2
LEGATO-HD study of laquinimod in Huntington's disease will be
presented at the scientific conference HSG 2018
Lund Sweden, November 8,
2018 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that
new data from the Phase 2 LEGATO-HD study of laquinimod in
Huntington's disease will be presented by Global Coordinating
Principal Investigator, Dr Ralf Reilmann at the annual Huntington
Study Group conference, HSG 2018, in Houston, Texas November 8-10.
The results will be presented at an oral session on November 9 and
as a poster titled "LEGATO-HD Study: A phase 2 study assessing the
efficacy and safety of laquinimod as a treatment for Huntington
disease". In addition to previously presented data on primary and
secondary endpoints and safety profile, results for exploratory
endpoints will be presented. Data for Q-Motor, a sensitive,
standardized rate-independent and unbiased measure, revealed
nominal improvement on motor coordination in patients treated with
laquinimod. These data together with the strong treatment effect on
brain volume loss propose a central effect of laquinimod in the
LEGATO-HD study. Additional analysis of the study is ongoing
and further results will be presented at upcoming scientific
meetings.
The poster will be available on Active Biotech's website
(www.activebiotech.com) in connection with the presentation.
ABOUT LEGATO-HD
LEGATO-HD is a multinational, multicenter,
randomized, double-blind, placebo-controlled, parallel-group Phase
2 study of laquinimod as a potential treatment in patients with HD.
The study was designed to evaluate three doses arms (0.5mg, 1.0mg,
and 1.5mg daily) versus placebo. The highest dose of 1.5 mg was
discontinued in January 2016 as a precautionary measure after
cardiovascular safety problems were observed in multiple sclerosis
studies with laquinimod of 1.2 mg and 1.5 mg respectively. No
similar issues were identified in the LEGATO-HD study.
The primary endpoint evaluating the change from
baseline at month 12 in the UHDRS-TMS for the 1.0 mg dose as
compared with placebo was not achieved. The secondary endpoint,
percent change in brain atrophy (caudate volume) from baseline at
12 months in the 1.0 mg dose as compared to placebo, was met. The
safety profile in the study was similar to that expected in the
patient population.
Exploratory outcome includes change of Unified
Huntington's Disease Rating Scale - Total Motor Score (UHDRS-TMS)
and percentage change in brain atrophy for the 0.5 mg dose, as well
as changes in measured motor function (Q-motor), cognitive
function, functional capacity and brain volumes for the 1.0 and 0.5
mg doses individually. The safety measures included adverse event
reporting, clinical laboratory tests, vital signs,
electrocardiograms, physical examinations and suicidality.
The study was conducted by Teva in collaboration
with the Huntington Study Group and European Huntington's Disease
Network. The study is registered as NCT02215616 on
clinicaltrials.gov and its EudraCT number is
2014-000418-75.
Lund November 8, 2018
Active Biotech AB (publ)
For further information, please
contact:
Helén Tuvesson, CEO
Tel +46 46 19 21 56Email: helen.tuvesson@activebiotech.com
Hans Kolam, CFO
Tel +46 46 19 20 44
Email: hans.kolam@activebiotech.com
Active Biotech AB (publ)
(NASDAQ Stockholm: ACTI) is a biotechnology company with focus on
neurodegenerative/inflammatory diseases and cancer. Laquinimod, an
orally administered small molecule with unique immunomodulatory
properties in development for neurodegenerative diseases. ANYARA,
an immunotherapy, in development for cancer indications in
partnership with NeoTX Therapeutics Ltd. Furthermore, commercial
activities are conducted for the tasquinimod, paquinimod and SILC
projects. Please visit http://www.activebiotech.com/en for more
information.
Active Biotech AB
(org.nr 556223-9227)
Box 724, 220 07 Lund
Tfn +46 46 19 20 00
The information
was submitted for publication at 13.00
p.m. CET on November 8, 2018.
New data from the Phase 2 LEGATO-HD
study will be presented at HSG 2018
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024